CSAAI 2023 Educational Meeting, A Midsummer Night's Wheeze
It is an exciting time in the field of allergy and immunology. This CME/CEU program is designed to allow attendees to continue exploring the field. Covered topics include EoE, Primary Immunodeficiency, Drug Allergy, Chronic Urticaria, Anaphylaxis and more!
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and California Society of Allergy, Asthma & Immunology (CSAAI). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 10 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 10 contact hours.
Allied health professionals
At the conclusion of this Activity learners should be able to:
- Analyze the common features of subcutaneous and sublingual immunotherapy and also haw they differ
- Apply knowledge of the differences and similarities of subcutaneous and sublingual immunotherapy to treatment decisions
- Perform differential diagnosis of GI eosinophilia
- Discuss management of patients with EGIDs
- Describe investigational monitoring and treatment options for patients with EGIDs
- Discuss limitations of routine diagnostic testing in chronic urticaria
- Apply clinical practice guidelines to the management of patients with chronic urticaria.
- Discuss management options for refractory chronic urticaria
- Identify common and uncommon patterns of anaphylaxis
- Evaluate patients for underlying causes of anaphylaxis
- Recommend optimal treatment plan for patients with a history of anaphylaxis
CSAAI 2023 Educational Meeting: A Midsummer Night’s Wheeze
FRIDAY, JUNE 23
1:00 pm Registration and Exhibits
2:50 pm Overview and Welcome, LanAnh Do, MD, President CSAAI
Friday Practice Management Symposium, featuring Bryan Martin, DO and J. Allen Meadows, MD, is brought to you by: California Society of Allergy, Asthma & Immunology and American College of Allergy, Asthma & Immunology
3:00 pm Physician Wellness: Beyond Burnout, Bryan Martin, DO
4:00 pm Top Allergy Papers
Perinatal Risk Factors and Infant Food Allergen Sensitization, Nina Sadigh, MD
Nivolumab plus Ipilimumab Induced IPEX-like Polyendocriopathy in Sarcomatoid Renal Cell Carcinoma, Christopher Hino, MD
5:00 pm Town Hall Meeting:2023 Coding Update for Allergists, J. Allen Meadows, M.D.
5:30pm Turning Policy into Action & Current Hot Topics, Timothy A. Murphy, MD (NonCME)
6:00 pm Adjourn
SATURDAY, JUNE 24
7:00 am Exhibits
8:00 am Welcome & Overview, Barbara Ariue, MD, Program Director CSAAI
8:10 am Present Status of SCIT and SLIT, Harold S. Nelson, M.D.
8:50 am Hypereosinophilia Syndrome, Princess Ogbogu, M.D.
9:30 am Insect Allergy Update, David B. K. Golden, M.D.
10:10 am Panel Discussion/Q&A
10:30 am Break and Exhibits
10:50 am Primary Immunodeficiency Disorders, Manish J. Butte, MD, PhD
11:30 am Refractory Chronic Spontaneous Urticaria, David A. Khan, M.D.
12:10 pm Anaphylaxis in Practice 2023, David B. K. Golden, M.D.
12:50 pm Panel Discussion/Q&A
1:05 pm Adjourn
SUNDAY, JUNE 25
6:30 am Annual Business Meeting Breakfast
7:00 am Break & Exhibits
8:00 am Welcome & Overview, Sonal Patel, MD, Secretary/Treasurer CSAAI
8:10 am Are You Dosing Properly?, Harold S. Nelson, M.D.
8:50 am Eosinophilic Esophagitis, Princess Ogbogu, M.D.
9:30 am Panel Discussion/Q&A
9:45 am Break & Exhibits
10:00 am Drug Allergy Practice Parameter, David A. Khan, M.D.
10:40 am Genetic Studies in patients with Primary Immunodeficiency Disorders, Manish J. Butte, MD, PhD
11:20 am Panel Discussion/Q&A
11:30 am Closing Remarks, LanAnh Do, MD, President CSAAI
11:45 am Adjourn
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.
Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All relevant financial relationships with ineligible companies have been mitigated.
The individuals listed below disclose the following financial relationships:
Manish J. Butte, MD, PhD – Speaker
Speaker: ADMA, CSL Behring, Grifols
Advisor: ADMA, Grifols, Pharming
David B. K. Golden, MD – Speaker
Consultant: ALK, Aquestive, IgGenix, Novartis, ThermoFisher
Speaker: Genentech, ThermoFisher
Independent contractor: Genentech, Novartis, ThermoFisher
J. Allen Meadows, MD – Speaker
Researcher: DBV Technologies
Speaker: Optinose, Pfizer, Regeneron, Sanofi/Genzyme, Teva
Consultant: Takeda, Teva
Harold S. Nelson, MD – Speaker
Consultant DSMB: Everest
Princess Ogbogu, MD – Speaker
Advisor: AstraZeneca, GSK, Sanofi
Researcher: AstraZeneca, Blueprint Medicines, GSK
Advisory Board: KalVista Pharmaceuticals
Sonal R. Patel, MD – Planner
Raffi Tachdjian, MD – Planner
Advisor: BioCryst, CSL Behring, KalVista, Pharming, Pharvaris, Sanofi/Regeneron, Takeda
Speaker: AstraZeneca, BioCryst, CSL Behring, Grifols, GSK, Pharming, Sanofi/Regeneron, Takeda
Independent contractor: BioCryst, CSL Behring, KalVista, Pharming, Pharvaris, Takeda
The following have no relevant financial relationships with ineligible companies to disclose:
Barbara Ariue, MD – Planner, Moderator
Sheila M. Bonilla, MD – Planner
LanAnh Do, MD – Planner, Moderator
Marilyn Li, MD – Planner
Myngoc Nguyen, MD – Planner
Javed Sheikh, MD – Planner
Christopher Hino, MD – Speaker
David A. Khan, MD – Speaker
Bryan Martin, DO – Speaker
Timothy A. Murphy, MD – Speaker
Nina Sadigh, MD – Speaker
Karol Anderson - Staff member, planner
- 10.00 AMA PRA Category 1 Credit™
- 10.00 Attendance
- 10.00 CBRN